However, whilst durvalumab has seen promise as a monotherapy in phase II clinical trials in MSI/dMMR CRC [57], in theory blocking the PD-1/PD-L1 axis at any point should elicit the same or similar effect, and wanted to combine with a checkpoint inhibitor that had FDA approval in CRC [2]. Here, CD274 is linked to colorectal carcinoma.